DanCann Pharma A/S appoints Martin Vedel Ernst as new Chief Financial Officer

Report this content

COPENHAGEN, Denmark, 10 May 2022 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the “Company”), a Danish company powered by cannabinoids, hereby announce that the Company appoints Martin Vedel Ernst as new Chief Financial Officer (“CFO”).

DanCann Pharma is currently undergoing a change from being an ambitious project to a growth company in operation. Therefore, the Company has recently upgraded significantly with key people both in the Board of Directors and in the Executive Management team.

In the future, DanCann Pharma's financial tasks will be handled by Martin Vedel Ernst. Martin Ernst has an educational background as Cand. Merc. Aud. from Copenhagen Business School and business experience from jobs as accountant at Deloitte and as Group Financial Controller at Vestas.

Martin Ernst is the latest in a series of significant business profiles that have come to DanCann Pharma in recent months. Sarah Maj Lykke-Kjeldsen has been hired as the new COO, Louise Conradsen has been appointed CEO of the subsidiary CannGros and the experienced investor relations capacity Tue Østergaard has been elected as a new member of the Board of Directors.

Comments from Martin Ernst, new CFO at DanCann Pharma:

- I look forward to being part of an ambitious and strong team in a fast-growing organization and industry. In collaboration with the Board of Directors and the Executive Board, I must help to ensure the best possible foundation for DanCann Pharma to maintain focus on its exciting journey. I am eager to get started and look forward to becoming more deeply involved in the ongoing process of professionalizing the Company's set up in the financial field, says Martin Ernst.

Comments from Jeppe Krog Rasmussen, CEO at DanCann Pharma:

- Martin has profound financial competencies from large Danish companies and will be a strong addition to our Executive Management team at DanCann Pharma. The business is running, and we are busy further developing and strengthening the organization to create great results.


Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

About DanCann Pharma

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed production and distribution Company based in Denmark. The Company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen.
For more information, visit:

For further information, please contact:

Jeppe Krog Rasmussen, CEO
Website: www.dancann.com